PL348049A1 - Pyridinium derivatives for the treatment of diabetic and aging−related vascular complications - Google Patents

Pyridinium derivatives for the treatment of diabetic and aging−related vascular complications

Info

Publication number
PL348049A1
PL348049A1 PL99348049A PL34804999A PL348049A1 PL 348049 A1 PL348049 A1 PL 348049A1 PL 99348049 A PL99348049 A PL 99348049A PL 34804999 A PL34804999 A PL 34804999A PL 348049 A1 PL348049 A1 PL 348049A1
Authority
PL
Poland
Prior art keywords
diabetic
aging
treatment
vascular complications
related vascular
Prior art date
Application number
PL99348049A
Other languages
English (en)
Inventor
Alangudi Sankaranarayanan
Original Assignee
Torrent Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torrent Pharmaceuticals Ltd filed Critical Torrent Pharmaceuticals Ltd
Publication of PL348049A1 publication Critical patent/PL348049A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
PL99348049A 1999-10-06 1999-10-15 Pyridinium derivatives for the treatment of diabetic and aging−related vascular complications PL348049A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN827CA1999 1999-10-06
PCT/IB1999/001687 WO2001025209A1 (en) 1999-10-06 1999-10-15 Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications

Publications (1)

Publication Number Publication Date
PL348049A1 true PL348049A1 (en) 2002-05-06

Family

ID=11084921

Family Applications (1)

Application Number Title Priority Date Filing Date
PL99348049A PL348049A1 (en) 1999-10-06 1999-10-15 Pyridinium derivatives for the treatment of diabetic and aging−related vascular complications

Country Status (12)

Country Link
EP (1) EP1220843A1 (de)
JP (1) JP2003511370A (de)
CN (1) CN1329597A (de)
AU (1) AU5994499A (de)
BR (1) BR9915962A (de)
CA (1) CA2351075A1 (de)
CZ (1) CZ20011808A3 (de)
HK (1) HK1044336A1 (de)
HU (1) HUP0301687A2 (de)
MX (1) MXPA02003496A (de)
PL (1) PL348049A1 (de)
WO (1) WO2001025209A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1355645A4 (de) * 2000-12-29 2005-02-23 Alteon Inc Methode zur behandlung von fibrosen oder anderen iiic indikationen
DE60111919T2 (de) * 2001-03-21 2006-04-20 Torrent Pharmaceuticals Ltd., Ahmedabad Pyridiniumverbindungen zur Behandlung von AGE-relatierten Krankheiten
CZ303214B6 (cs) * 2001-03-21 2012-05-30 Torrent Pharmaceuticals Ltd Pyridiniová sloucenina, zpusob její výroby, její použití, farmaceutický prostredek ji obsahující, zpusob jeho výroby a jeho použití
BR0208561A (pt) * 2001-04-05 2004-03-30 Torrent Pharmaceuticals Ltd Compostos heterocìclicos para complicações vasculares diabéticas e relacionadas ao envelhecimento
HUP0104831A2 (hu) * 2001-10-19 2003-08-28 Torrent Pharmaceuticals Ltd. Készítmény és eljárás piridíniumszármazékok gyógyászati alkalmazására
GB0328314D0 (en) * 2003-12-05 2004-01-07 Univ Bath Therapeutics
WO2007132179A2 (en) * 2006-05-15 2007-11-22 University Of Bath Therapeutics comprising pyridinium derivatives
JP2009155315A (ja) * 2007-12-26 2009-07-16 Fujiyakuhin Co Ltd 注射剤
JP2012526103A (ja) * 2009-05-07 2012-10-25 トレント・ファーマシューティカルズ・リミテッド 糖尿病の治療に有用なピペリジン誘導体
ES2899694T3 (es) * 2012-10-05 2022-03-14 Sphaera Pharma Pte Ltd Compuestos novedosos, su síntesis y sus usos
SG11201708140RA (en) * 2015-04-08 2017-11-29 Torrent Pharmaceuticals Ltd Novel pyridinium compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH335521A (de) * 1955-06-02 1959-01-15 Cilag Ag Verfahren zur Herstellung neuer quaternärer Salze
US3318787A (en) * 1964-02-07 1967-05-09 Udylite Corp Electrodeposition of zinc
US3823076A (en) * 1972-05-23 1974-07-09 Du Pont Zinc electroplating additive
JPS5936247B2 (ja) * 1977-04-20 1984-09-03 ティーディーケイ株式会社 電気的表示装置
JPS55138742A (en) * 1979-04-17 1980-10-29 Fuji Photo Film Co Ltd Silver halide emulsion developing method
JPH0253759A (ja) * 1988-08-18 1990-02-22 Hamari Yakuhin Kogyo Kk 新規な４級アンモニウム化合物
DD275872A1 (de) * 1988-09-27 1990-02-07 Univ Dresden Tech Verfahren zur herstellung von 5h-pyrido[1',2':1,2]imidazo[5,4-c]chinolin-6-onen
CN1142778C (zh) * 1995-01-18 2004-03-24 奥尔顿有限公司 噻唑鎓化合物用于预防和逆转高级糖基化终产物形成的用途
CA2285556A1 (en) * 1997-04-04 1998-10-15 Smithkline Beecham Corporation Calcilytic compounds

Also Published As

Publication number Publication date
BR9915962A (pt) 2003-01-07
EP1220843A1 (de) 2002-07-10
WO2001025209A1 (en) 2001-04-12
JP2003511370A (ja) 2003-03-25
AU5994499A (en) 2001-05-10
CA2351075A1 (en) 2001-04-12
CZ20011808A3 (cs) 2001-08-15
HUP0301687A2 (hu) 2003-08-28
HK1044336A1 (zh) 2002-10-18
MXPA02003496A (es) 2005-06-20
CN1329597A (zh) 2002-01-02

Similar Documents

Publication Publication Date Title
AU1781901A (en) Expandable venous cannula and method of use
AU5056300A (en) Devices and compounds for treating arterial restenosis
AU5788300A (en) Medical treatment method and kit
HK1048949A1 (en) Method and composition for the treatment of scars
MXPA01009415A (es) COMPOSICION DE ACIDO ASCORBICO Y METODO PARA TRATAMIENTO DE PIEL DAnADA O ENVEJECIDA.
AU4171500A (en) Flupirtine in the treatment of fibromyalgia and related conditions
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
AU4717301A (en) Catheter assembly and method of use
HUP0104116A3 (en) Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
EP1305018A4 (de) Methoden und zusammenstellungen zur prophylaxe und/oder behandlung von diabetes und zur glukoseregulierung
PL348049A1 (en) Pyridinium derivatives for the treatment of diabetic and aging−related vascular complications
HUP0200738A3 (en) Method of the treatment of incontinence
AU1794801A (en) Method for treatment and prevention of physiological shock
AU1321101A (en) Cholesterol lowering and blood lipids lowering composition
AU2001244461A1 (en) Venous line catheter and method of operating the same
AU1792901A (en) Methods for treating and preventing diabetic complications
EP1089731A4 (de) Zusammensetzungen und verfahren zur behandlung von erhöhtem blutcholesterolspiegel
AU2420101A (en) Method and composition for the treatment of pain
AU2566201A (en) Compounds and methods for the treatment of pain
AU6648200A (en) Method and composition for preventing or treating adverse physiological effects associated with cardiac disease
HUP0300043A3 (en) Method and composition for the treatment of pain
EP1089732A4 (de) Zusammenstellungen und methoden zur behandlung von erhöhtem blutcholesterolspiegel
IL150208A0 (en) Compound and method for the treatment of pain
AU2420201A (en) Compounds and methods for the treatment of pain
AU2899099A (en) Composition for treatment and prevention of coronary artery disease

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)